MedTrace Logo

Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer

NCT01989780 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2022-08-04

No results posted yet for this study

Summary

To compare continuing bevacizumab + paclitaxel or switching to bevacizumab + endocrine maintenance therapy followed by bevacizumab + paclitaxel, after 1st line induction therapy with bevacizumab + paclitaxel in ER+HER2- advanced or metastatic breast cancer.

Conditions

Interventions

DRUG

Paclitaxel

DRUG

Bevacizumab

DRUG

Letrozole

DRUG

Anastrozole

DRUG

Exemestane

DRUG

Fulvestrant

DRUG

Goserelin

DRUG

leuprorelin

Sponsors & Collaborators

  • Chugai Pharmaceutical

    collaborator INDUSTRY

  • Japan Breast Cancer Research Group

    lead OTHER

Principal Investigators

  • Masakazu Toi, MD, PhD · Kyoto University, Graduate School of Medicine

  • Shigehira Saji, MD, PhD · Fukushima Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2018-06-30
Completion
2019-06-30

Countries

  • Japan

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01989780 on ClinicalTrials.gov